Zentalis Pharmaceuticals, Inc. · NASDAQ:ZNTL

Zentalis Pharmaceuticals — SGO Annual Meeting on Women's Cancer 2025

14 slides from Zentalis Pharmaceuticals's conference presentation, Mar 17, 2025

  1. Slide 1: SGO Annual Meeting on Women's Cancer, Seattle 2025

    Exhibit 99.2 MULTIPLY YOUR IMPACT SGO ANNUAL MEETING ON WOMEN’S CANCER SEATTLE, WA + 2025

  2. Slide 2: Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in PROC

    Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes From Part 1b of the DENALI Study (GOG-3066) Fiona Simpkins1,Alexandra Leary2, Lyndsay Willmott3, Bradley J. Monk4, Jean-Sébastien Frenel5, David C. Starks6, Meena Okera7, Angeles Alvarez

  3. Slide 3: Financial Disclosures for Fiona Simpkins

    Financial Disclosures for Fiona Simpkins I have the following financial relationships with ACCME defined ineligible companies to report over the past 24 months: • Consulting/Advisory Role: AstraZeneca; GlaxoSmithKline; Zentalis, Repare Therapeutics, FoRx Therapeutics • Research Funding to Institutio

  4. Slide 4: Unlabeled/Investigational Uses

    I will be discussing the unlabeled or investigational use of Azenosertib, a WEE1 inhibitor, from Zentalis Pharmaceuticals Unlabeled/Investigational Uses

  5. Slide 5: Cyclin E1 Overexpression and CCNE1 Amplified Ovarian Cancers Have Worse Outcomes

    Survival according to CCNE1 amplification status1 Ovarian Cancer Patients With Cyclin E1 Overexpression and/or CCNE1 Amplified Ovarian Cancers Have Worse Outcomes aTiming of tissue collection was not disclosed. OS, overall survival; PFS, progression-free survival. 1. Stronach EA, et al. Mol Cancer R

  6. Slide 6: Targeting WEE1 with Azenosertib Exploits Critical Cell Cycle Checkpoints

    • Cyclin E1 protein overexpression results in cells moving prematurely from G1 to S, there by increasing reliance on the G2-M checkpoint to allow DNA repair1,2 • WEE1 is a master regulator of the cell cycle acting as a brake at G1-S and G2-M to allow DNA repair3 • Targeting WEE1 with azenosertib ult

  7. Slide 7: DENALI (GOG-3066) Part 1b: Study Design

    Part 1b: Study design ✓ PROC ✓ 1-5 prior lines of therapy ✓ Prior bevacizumab ✓ All comers (irrespective Cyclin E1 status) Key eligibility criteria Endpoints PFSb Safety and tolerability ORR, DORa Enrollment (N=102) Azenosertib 400 mg QD 5:2 NCT05128825 Enrollment complete P re s c re e n in g / T i

  8. Slide 8: DENALI Part 1b: Patient Baseline Characteristics

    Characteristicsa (N=102) Median age (range), years 66 (34-82) Race, n (%) White 70 (69) Black/African American 6 (6) Asian 3 (3) Otherb 1 (1) Not reported 22 (22) ECOG PS, n (%) 0 53 (52) 1 49 (48) Prior lines of treatment Median (range) 3 (1-5) 1-2, n (%) 35 (34) 3-4, n (%) 57 (56) 5, n (%) 10 (10)

  9. Slide 9: Part 1b: Cyclin E1+ by IHC is a Biomarker Predicting Response to Azenosertib

    All treated patients (N=102) ORR in response-evaluablec patients, % (n/N; 95% CI) 20.4 (19/93; 12.8-30.1) ORR, ITTa % (n/N; 95% CI) 18.6 (19/102; 11.6-27.6) Cyclin E1 IHC+ (n=48) ORR in response-evaluablec patients, % (n/N; 95% CI) 34.9 (15/43; 21.0-50.9) ORR, ITTa % (n/N; 95% CI) 31.3 (15/48; 18.7-

  10. Slide 10: Part 1b: Duration of Response in Cyclin E1 IHC+ Ovarian Cancer

    17 180 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 P a ti e n ts amDOR is subject to change, there are 4 ongoing responders as of the January 13, 2025 data cutoff. IHC, immunohistochemistry; cPR, confirmed partial response; SD, stable disease; PD, progressive disease; mDOR, median duration of response; m

  11. Slide 11: Part 1b: Safety and Tolerability Summary

    12 11 11 4 7 3 2 3 16 7 3 5 1 0 25 50 75 100 Grade ≥3 Grades 1-2 66 51 15 14 60 15 13 13 12 11 11 12 Total 15 23 % Patients Hematological Thrombocytopenia Anemia Neutropenia Gastrointestinal Nausea Diarrhea Decreased appetite Constipation Dysgeusia Abdominal pain Other Fatigue ALT increased Asthenia

  12. Slide 12: DENALI Phase 2 Study of Azenosertib in Cyclin E1+ PROC

    Part 2 Key eligibility criteria ✓ PROC ✓ Cyclin E1+ IHC ✓ 1-3 prior lines of therapy ✓ 4 if prior mirvetuximab P re s c re e n in g / T is s u e C o n s e n t In te ri m A n a ly s is b Patients with Cyclin E1+ tumors Azenosertib 400 mg 5:2 Azenosertib 300 mg 5:2 1:1 randomization Azenosertib (dose

  13. Slide 13: Conclusions: Azenosertib warrants further development in Cyclin E1+ PROC

    Azenosertib warrants further development in Cyclin E1+ PROC in Part 2 of the ongoing DENALI study • Cyclin E1+ / overexpression by IHC represents ~ 50% of PROC • Cyclin E1+ IHC more than doubles the eligible patient population beyond CCNE1 amp • Azenosertib demonstrates ORR of ~35% in evaluablea pat

  14. Slide 14: Study Sponsor and Enrolling Sites

    This study was sponsored by Zentalis Pharmaceuticals, Inc. Enrolling sites • Alliance Cancer Specialists, PC − USOR – Wynnewood • Arizona Oncology Associates, PC – HAL • Avera Cancer Institute • Baystate Medical Center • Burnside War Memorial Hospital − The Brian Fricker Oncology Centre • Cancer Res

Zentalis Pharmaceuticals — SGO Annual Meeting on Women's Cancer 2025 on 6ix